There are currently 79 active clinical trials seeking participants for Chronic Lymphocytic Leukemia research studies. The states with the highest number of trials for Autism participants are California, Ohio, Illinois and Michigan.
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
NCT05797233
Recruiting
Background: About 23,000 people die from B-cell cancers in the US each year. These cancers, often called leukemia or lymphoma, affect a type of white blood cell called B cells. These cancers are difficult to treat, and the therapies used can have bad side effects. Researchers want to try a new type of treatment. This new treatment uses a patient s own immune cells (T cells) that are modified to carry genes (chimeric antigen receptor, or CAR T cells) to kill cancer cells. Objective: To test a... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell
Register for Updates
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
NCT03622788
Recruiting
This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, whit... Read More
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
02/12/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
Register for Updates
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT05405309
Recruiting
This is an open-label, multicenter, phase Ib/II study of the combination of RP-3500 and olaparib in R/R CLL patients with DDR deficiencies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)
NCT04844528
Recruiting
This is a randomized, phase II, double-blind, placebo-controlled trial with planned crossover to the intervention arm after 1 year. Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
NCT05183854
Recruiting
This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia. PCV20 and PPSV23 are both vaccines that protect against bacteria that cause pneumococcal disease. Giving these vaccinations as series may make a stronger immune response and prevent against pneumococcal infections in patients with chronic lymphocytic leukemia.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Financial Difficulty in Patients With Blood Cancer
NCT05212233
Recruiting
This is a hypothesis-driven, observational, cross-sectional, multi-site study of the financial difficulties experienced by patients undergoing treatment for multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). It is composed of a patient survey (n=250) (Appendix A), a physician survey (n=100) (Appendix B), and a practice survey completed by each site enrolling patients onto this study (Appendix C). A subset of enrolled patients (n=35) will be invited to participate in an optional second... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
02/07/2024
Locations: Mayo Clinic Cancer Center, Phoenix, Arizona +2 locations
Conditions: Chronic Lymphocytic Leukemia, Multiple Myeloma
Register for Updates
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
NCT05672355
Recruiting
This phase II trial compares the effect of the GEO-CM04S1 vaccine with the current standard of care vaccine in preventing COVID-19 infections in patients with chronic lymphocytic leukemia (CLL). The GEO-CM04S1 vaccine uses a modified vaccinia virus (MVA) backbone that may be more effective at boosting COVID-19 immunity in patients with poor immune responses. MVA strongly induces T cell expansion (infection fighting blood cells) even in the background of a suppressed immune system, which is the c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Chronic Lymphocytic Leukemia, COVID-19 Infection
Register for Updates
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493
Recruiting
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Mayo Clinic Arizona, Phoenix, Arizona +195 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743
Recruiting
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six years.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Genesis Cancer Center, Hot Springs, Arkansas +203 locations
Conditions: Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
Register for Updates
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
NCT05694364
Recruiting
The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and solid tumor triple negative breast cancer (TNBC) malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Triple Negative Breast Cancer Malignancies
Register for Updates
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
NCT02952508
Recruiting
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/19/2024
Locations: Cellectar Biosciences site, Los Angeles, California +51 locations
Conditions: Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Central Nervous System Lymphoma
Register for Updates
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
NCT06151730
Recruiting
This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.
Gender:
All
Ages:
All
Trial Updated:
01/10/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Register for Updates